MG-ADL Subdomain Score Changes With Eculizumab or Ravulizumab: An Analysis of the Global MG SPOTLIGHT Registry (P4-9.008)

Vern Juel; Samir Macwan; Francesco Saccà; Andrew Gordon; Lida Zeinali; James Winkley; Chuang LIU; Gary Cutter; Dubravka Dodig; Joshua Alpers; Rup Tandan

doi:10.1212/wnl.0000000000215408

June 9, 2026Neurology

MG-ADL Subdomain Score Changes With Eculizumab or Ravulizumab: An Analysis of the Global MG SPOTLIGHT Registry (P4-9.008)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate how MG-ADL subdomain scores change after starting C5 inhibitor therapy in patients with generalized myasthenia gravis.
Utilized data from the Global MG SPOTLIGHT Registry
Analyzed MG-ADL scores after initiating eculizumab or ravulizumab therapy
Focused on patients diagnosed with generalized myasthenia gravis.
Significant improvements in MG-ADL scores were observed post-therapy initiation with eculizumab or ravulizumab.
Positive changes were noted among the majority of patients treated with C5 inhibitors.

Implication

Assesses MG-ADL score changes after C5 inhibitor therapy in generalized myasthenia gravis, suggesting therapeutic benefits.

Abstract

To assess changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) subdomain scores after complement component 5 (C5) inhibitor therapy (C5IT, eculizumab and ravulizumab) initiation among patients with generalized myasthenia gravis (gMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Juel et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f0561a5 https://doi.org/10.1212/wnl.0000000000215408

View Full Paper

Ask AI

Bookmark

Share

MG-ADL Subdomain Score Changes With Eculizumab or Ravulizumab: An Analysis of the Global MG SPOTLIGHT Registry (P4-9.008)

Key Points

Implication

Abstract

Discussion

Cite This Study

MG-ADL Subdomain Score Changes With Eculizumab or Ravulizumab: An Analysis of the Global MG SPOTLIGHT Registry (P4-9.008)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading